Breaking
RAPS Euro Convergence: Top Regulatory Insights - Day 1European Research Revolution: Day 1 HighlightsRAPS Euro Convergence: Key Regulatory Updates - Day 1
🇪🇺 EMA

Prostate Cancer

Page 1 • 1 item

Global prostate cancer market intelligence for pharma BD, investors & analysts. Track drug development, clinical trials, and regulatory approvals.

FDA Advisory Committee Recommends AstraZeneca's TRUQAP for PTEN-Deficient Metastatic Prostate Cancer
NewsOncology - Prostate CancerMay 1, 2026

FDA Advisory Committee Recommends AstraZeneca's TRUQAP for PTEN-Deficient Metastatic Prostate Cancer

FDA's Oncologic Drugs Advisory Committee recognizes favorable benefit-risk profile for TRUQAP (capivasertib) in PTEN-deficient metastatic prostate cancer treatment.

Dr. Amina Farouk